Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT01556490 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT01556490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01556490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2012
Completion date
April 30, 2022
Enrollment
526 (actual)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma